James Dean

664 total citations
24 papers, 505 citations indexed

About

James Dean is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Genetics. According to data from OpenAlex, James Dean has authored 24 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 8 papers in Genetics. Recurrent topics in James Dean's work include Asthma and respiratory diseases (8 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers) and Chronic Myeloid Leukemia Treatments (7 papers). James Dean is often cited by papers focused on Asthma and respiratory diseases (8 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers) and Chronic Myeloid Leukemia Treatments (7 papers). James Dean collaborates with scholars based in United Kingdom, United States and Italy. James Dean's co-authors include Peter S. Nelson, Claes Båvik, Ilsa Coleman, Beatrice S. Knudsen, Dave Singh, Augusta Beech, Umme Kolsum, Paul G. Hitchen, Andrew Higham and Ruben A. Mesa and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

James Dean

23 papers receiving 502 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Dean United Kingdom 8 229 212 134 111 103 24 505
Guosheng Lin China 11 63 0.3× 276 1.3× 109 0.8× 94 0.8× 217 2.1× 25 555
Marta Kovatcheva Spain 8 78 0.3× 205 1.0× 266 2.0× 286 2.6× 46 0.4× 12 547
Silvia Gisfredi Italy 14 123 0.5× 241 1.1× 169 1.3× 219 2.0× 37 0.4× 25 598
H Chapuis France 11 56 0.2× 251 1.2× 106 0.8× 127 1.1× 30 0.3× 25 528
Maria Luposella Italy 15 55 0.2× 328 1.5× 118 0.9× 166 1.5× 381 3.7× 20 668
Susanna Mannisto Finland 13 30 0.1× 299 1.4× 153 1.1× 128 1.2× 135 1.3× 26 661
Sophie Kaltenbach France 10 52 0.2× 237 1.1× 44 0.3× 71 0.6× 80 0.8× 21 421
Louise Westberg Strejby Christensen Denmark 10 44 0.2× 163 0.8× 110 0.8× 118 1.1× 84 0.8× 25 521
Paola Sterpetti Italy 9 47 0.2× 378 1.8× 78 0.6× 121 1.1× 61 0.6× 11 646
Ondřej Havránek Czechia 13 31 0.1× 240 1.1× 47 0.4× 154 1.4× 85 0.8× 45 538

Countries citing papers authored by James Dean

Since Specialization
Citations

This map shows the geographic impact of James Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Dean more than expected).

Fields of papers citing papers by James Dean

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Dean. The network helps show where James Dean may publish in the future.

Co-authorship network of co-authors of James Dean

This figure shows the co-authorship network connecting the top 25 collaborators of James Dean. A scholar is included among the top collaborators of James Dean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Dean. James Dean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2024). Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S179–S179. 5 indexed citations
2.
Dean, James, Stephen J. Fowler, Dave Singh, & Augusta Beech. (2024). Expiratory flow limitation development index (ELDI): a novel method of assessing respiratory mechanics in COPD. Respiratory Research. 25(1). 357–357. 1 indexed citations
3.
Higham, Andrew, Augusta Beech, James Dean, & Dave Singh. (2023). Exhaled nitric oxide, eosinophils and current smoking in COPD patients. ERJ Open Research. 9(6). 686–2023. 17 indexed citations
4.
Dean, James & Dave Singh. (2023). Investigation of the Methodology of Specific Airway Resistance Measurements in COPD. International Journal of COPD. Volume 18. 2555–2563.
5.
Beech, Augusta, Natalie Jackson, James Dean, & Dave Singh. (2022). Expiratory flow limitation in a cohort of highly symptomatic COPD patients. ERJ Open Research. 8(2). 680–2021. 6 indexed citations
6.
Dean, James, et al.. (2021). Methacholine challenges: comparison of different tidal breathing challenge methods. ERJ Open Research. 7(4). 282–2021. 2 indexed citations
7.
8.
Singh, Dave, Naimat Ullah Khan, James Dean, et al.. (2019). FEV1 recovery following methacholine challenge in asthma: Variability and comparison of methods. Pulmonary Pharmacology & Therapeutics. 60. 101876–101876. 1 indexed citations
9.
Dean, James, et al.. (2017). Clinical characteristics of COPD patients with tidal expiratory flow limitation. International Journal of COPD. Volume 12. 1503–1506. 24 indexed citations
10.
Harrison, Claire, Miklós Egyed, Anita Szőke, et al.. (2016). Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.. Journal of Clinical Oncology. 34(15_suppl). 7011–7011. 2 indexed citations
11.
Mesa, Ruben A., Claire Harrison, Francisco Cervantes, et al.. (2016). Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.. Journal of Clinical Oncology. 34(15_suppl). 7067–7067. 1 indexed citations
12.
Al‐Fayoumi, Suliman, et al.. (2015). Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor. Blood. 126(23). 5178–5178. 1 indexed citations
13.
14.
Lafeuille, Marie‐Hélène, et al.. (2013). Observed Abiraterone Acetate Utilization By Prostate Cancer (Pc) Patients In A Large Administrative Claims Database In The United States. Value in Health. 16(3). A144–A144. 1 indexed citations
15.
Wright, Jonathan L., William Proctor Harris, Heather H. Cheng, et al.. (2013). Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder.. Journal of Clinical Oncology. 31(6_suppl). 267–267. 1 indexed citations
16.
Dean, James, Cynthia C.T. Sprenger, Junxiang Wan, et al.. (2013). Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer Trial: Effects of Obesity and Androgen Deprivation. The Journal of Clinical Endocrinology & Metabolism. 98(5). E820–E828. 23 indexed citations
17.
Dean, James, Bruce Montgomery, Jie Wan, et al.. (2011). On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial.. Journal of Clinical Oncology. 29(7_suppl). 153–153. 3 indexed citations
18.
Dean, James, Stephen R. Plymate, B.L. Dalkin, et al.. (2010). Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: A phase II trial.. Journal of Clinical Oncology. 28(15_suppl). TPS251–TPS251. 1 indexed citations
19.
Dean, James & Peter S. Nelson. (2008). Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. British Journal of Cancer. 98(2). 245–249. 35 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guosheng Lin Breakdown of academic impact, for papers by Marta Kovatcheva Breakdown of academic impact, for papers by Silvia Gisfredi Breakdown of academic impact, for papers by H Chapuis Breakdown of academic impact, for papers by Maria Luposella Breakdown of academic impact, for papers by Susanna Mannisto Breakdown of academic impact, for papers by Sophie Kaltenbach Breakdown of academic impact, for papers by Louise Westberg Strejby Christensen Breakdown of academic impact, for papers by Paola Sterpetti Breakdown of academic impact, for papers by Ondřej Havránek
Rankless by CCL
2026